AlloVir (formerly ViraCyte) is a company that develops and delivers transformative cell therapies for patients suffering from life-threatening virus-associated diseases. It focuses on the clinical development of novel cell therapies designed to restore natural T-cell immunity against devastating virus-associated diseases in immunocompromised patients, including stem cell and organ transplant recipients.
|HQ||Houston, TX, US||Map|
Revenue growth (FY, 2019 - FY, 2020), %
Net income (FY, 2020)
EBIT (FY, 2020)
Market capitalization (12-Nov-2021)
Closing stock price (12-Nov-2021)
|Company Name||Date||Deal Size|
|AlloVir International Designated Activity Company|
|AlloVir Italia S.R.L.|
|AlloVir Securities Corporation|
AlloVir has 249 Twitter Followers. The number of followers has increased 1.2% month over month and increased 7.5% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was AlloVir founded?
AlloVir was founded in 2013.
Who are AlloVir key executives?
AlloVir's key executives are Ann Leen, Agustin Melian and Edward Miller.
How many employees does AlloVir have?
AlloVir has 21 employees.
Who are AlloVir competitors?
Competitors of AlloVir include Fate Therapeutics, Neurocrine Biosciences and Adaptive Biotechnologies.
Where is AlloVir headquarters?
AlloVir headquarters is located at 2925 Richmond Ave, Houston.
Where are AlloVir offices?
AlloVir has offices in Houston, Cambridge, Waltham and Milano.
How many offices does AlloVir have?
AlloVir has 4 offices.
Receive alerts for 300+ data fields across thousands of companies